Abstract
Coronavirus disease 2019 (COVID-19) will likely remain a major public health burden; accurate forecast of COVID-19 epidemic outcomes several months into the future is needed to support more proactive planning. Here, we propose strategies to address three major forecast challenges, i.e., error growth, the emergence of new variants, and infection seasonality. Using these strategies in combination we generate retrospective predictions of COVID-19 cases and mortality 6 months in the future for 10 representative US states during July 2020 to September 2022. The optimized forecast approach using all three strategies consistently outperformed a baseline forecast approach across different variant waves and locations, for all forecast targets; overall, probabilistic forecast accuracy improved by 64% and 38% and point prediction accuracy by 133% and 87% for cases and deaths, respectively. Given this superior forecast skill, the strategies could support sensible long-lead forecast of COVID-19 and possibly other infectious diseases.
One sentence summary To support more proactive planning, we propose approaches that substantially improve long-lead COVID-19 forecast accuracy.
Competing Interest Statement
JS and Columbia University disclose partial ownership of SK Analytics. JS discloses consulting for BNI.
Funding Statement
This study was supported by the National Institute of Allergy and Infectious Diseases (AI145883 and AI163023), the Centers for Disease Control and Prevention (CDC) and the Council of State and Territorial Epidemiologists (CSTE; contract no.: NU38OT00297), and the CDC Center for Forecasting and Outbreak Analytics (contract no.: 75D30122C14289).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data used in this study are publicly available as described in the main text.
